National Healthcare Security Administration

National Healthcare Security Administration
Name	National Healthcare Security Administration
Formed	2018
Headquarters	Beijing

National Healthcare Security Administration is a Chinese administrative agency responsible for administering social health insurance, pharmaceutical reimbursement, and related welfare programs. It operates within the framework of the State Council and interacts with multiple ministries, provincial authorities, and international bodies to implement policy, manage funds, and oversee drug procurement and payment systems.

History

The agency was created during a period of institutional reform following directives from the 13th National People's Congress and reorganization efforts led by the State Council under the premiership of Li Keqiang. Its formation consolidated functions previously dispersed among the Ministry of Human Resources and Social Security, the Ministry of Health and Family Planning Commission, and provincial authorities. The creation reflected priorities set by the Chinese Communist Party leadership, echoing reform themes from the Third Plenum and the Decision of the Central Committee. Early initiatives linked to wider campaigns such as the Healthy China 2030 strategy and coordination with the National Development and Reform Commission on health investment.

Organization and Leadership

The Administration is structured with divisions handling insurance operations, drug policy, budgeting, and auditing, and it reports administratively to the State Council. Leadership appointments have been announced alongside personnel changes in the Office of the Central Financial and Economic Affairs Commission and other central organs. Senior officials liaise with provincial counterparts in Guangdong, Sichuan, Jiangsu, and Henan to coordinate local implementation. The agency collaborates with regulatory bodies including the National Medical Products Administration and the National Health Commission, and it interacts with external institutions like the World Health Organization and the World Bank on technical cooperation.

Functions and Responsibilities

Mandates include administration of basic medical insurance, catastrophic illness funds, and maternity insurance as specified under statutes influenced by the Social Insurance Law of the People's Republic of China. Responsibilities encompass management of reimbursement rates, formulary design, and procurement oversight in line with standards promoted by the China Food and Drug Administration predecessor and current drug regulators. The Administration implements purchasing models such as centralized procurement and volume-based procurement first piloted in provinces like Shandong and Shanghai. It enforces audit mechanisms reminiscent of financial oversight conducted by the National Audit Office of the People's Republic of China and cooperates with courts including the Supreme People's Court on disputes over benefits.

Policies and Programs

Major programs administered include the basic medical insurance for urban employees, basic medical insurance for urban and rural residents, and catastrophic illness coverage, aligning with directives from the State Council and policy papers from the Central Committee of the Chinese Communist Party. The agency has led price negotiation rounds with multinational and domestic pharmaceutical companies, a process comparable to negotiations seen in jurisdictions such as Germany, Japan, and South Korea. Pilot initiatives on digital claims processing have drawn on technologies promoted in national initiatives like Made in China 2025 and platforms interoperable with systems in provincial capitals such as Beijing and Shenzhen. Policy coordination has involved ministries including the Ministry of Finance and agencies such as the China Banking and Insurance Regulatory Commission when addressing fiscal sustainability and insurer solvency.

Funding and Budget

Funding sources derive from payroll-based contributions, government subsidies allocated through annual budgets approved by provincial people's congresses, and transfers governed by fiscal policy debates in forums such as sessions of the National People's Congress. Budgetary oversight involves the Ministry of Finance and is subject to audit by the National Audit Office of the People's Republic of China. Expenditure items include reimbursements for inpatient and outpatient care, drug purchases via centralized procurement, and payments to designated healthcare providers including municipal hospitals like Peking Union Medical College Hospital and tertiary centers in Wuhan and Chengdu. Financial pressures related to demographic change echo analyses published by institutions such as the Asian Development Bank and the International Monetary Fund.

International Cooperation and Recognition

The Administration engages in technical exchanges and cooperative projects with the World Health Organization, the World Bank, and bilateral partners including agencies from Germany and Australia on health financing reform and pharmaceutical policy. It has been cited in comparative studies by research centers such as the Harvard T.H. Chan School of Public Health and the London School of Economics for innovations in procurement and reimbursement. Participation in global forums like the United Nations and regional mechanisms such as the Asia-Pacific Economic Cooperation has increased visibility of Chinese approaches to social health insurance, attracting attention from scholars at institutions including Johns Hopkins University and the European Commission.

Category:Healthcare in the People's Republic of China Category:State Council (China)